Treatment of Hypertension During Pregnancy: Drugs to be Avoided and Drugs to be Used

  • Stephen N. Sturgiss
  • Marshall D. Lindheimer
  • John M. Davison


This chapter focuses on hypertension during pregnancy, a common clinical problem and one of the main causes of maternal and perinatal morbidity and mortality. Drug treatment of hypertension during pregnancy is controversial not only because of our lack of understanding of cardiovascular physiology in normal pregnancy, but also because there is a clinical spectrum of hypertensive disorders in pregnancy making an aetiologic diagnosis difficult by clinical criteria alone. Therefore, before considering drugs to be avoided and drugs to be used, it is essential to briefly review the course of normal blood pressure during pregnancy, the classification of hypertensive disorders which complicate pregnancy and the pathophysiology of these disorders in pregnancy, focusing on preeclampsia.


Obstet Gynecol Pulmonary Capillary Wedge Pressure Magnesium Sulphate Chronic Hypertension Uterine Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Friedman EA, Neff RK: Pregnancy hypertension: a systematic evaluation of clinical diagnostic criteria. PSG Publishing Company, Littleton MA, 1977.Google Scholar
  2. 2.
    Page EW, Christianson R: The impact of mean arterial pressure in the middle trimester upon the outcome of pregnancy. Am J Obstet Gynecol, 125: 740–746, 1976.PubMedGoogle Scholar
  3. 3.
    Fletcher AE, Bulpitt CJ: A review of clinical trials in pregnancy hypertension. In: “Hypertension in pregnancy” (Ed PC Rubin), Elsevier, New York, 1988, pp 186–201.Google Scholar
  4. 4.
    Rubin PC, Butters L, Clark DM, Reynolds B, Sumner DJ, Steedman D, Low RA, Reid JL: Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet, I: 431–434, 1983.Google Scholar
  5. 5.
    Whichman K, Ryden G, Karlberg G: A placebo controlled trial of metoprolol in the treatment of hypertension during pregnancy. Scand J Clin Lab Invest, 44(Suppl 169): 90–95, 1984.Google Scholar
  6. 6.
    Leather HM, Humphreys DM, Baker P, Chadd MA: A controlled trial of hypertensive agents in hypertension of pregnancy. Lancet, II: 488–490, 1968.Google Scholar
  7. 7.
    Walker JJ, Crooks A, Erwin L, Calder AA: Labetalol in pregnancy-induced hypertension: fetal and maternal effects. In: “The investigation labetalol in the management of hypertension in pregnancy” (Eds A Riley, EM Symonds), Excerpta Medica, Amsterdam, 1982, pp 148–160.Google Scholar
  8. 8.
    Redman CWG, Beilin LJ, Bonnar J: Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynecol, 84: 419–426, 1977.Google Scholar
  9. 9.
    Venuto RC, Cox JW, Stein JH, Ferris TF: The effect of changes in perfusion pressure on uteroplacental blood flow in the pregnant rabbit J Clin Invest, 57: 938–941, 1976.PubMedGoogle Scholar
  10. 10.
    Ladner C, Brinkman CR III, Weston P, Assali NS: Dynamics of uterine circulation in pregnant and nonpregnant sheep. Am J Physiol, 218: 257–263, 1970.PubMedGoogle Scholar
  11. 11.
    De Swiet M, Hoffbrand BI: Effect of bethanidine on placental blood flow in conscious rabbits. Am J Obstet Gynecol, 111: 374–378, 1971.PubMedGoogle Scholar
  12. 12.
    Greiss FC Jr: Uterine pressure flow relationships. In: “Uterine and placental blood flow” (Eds AH Moawad, MD Lindheimer), Masson, New York, 1982, pp 67–71.Google Scholar
  13. 13.
    Ferris TF: Toxaemia and hypertension. In: “Medical complications during pregnancy” (Eds GN Burrow, TF Ferris), 3rd Edition, WB Saunders, Philadelphia, 1988, pp 1–33.Google Scholar
  14. 14.
    Gallery EDM, Saunders DM, Hunyor SM, Gyory AZ: Randomised comparison of methyldopa and Oxprenolol for treatment of hypertension in pregnancy. Br Med J, I: 1591–1594, 1979.Google Scholar
  15. 15.
    Sibai BM, Ardella TM, Anderson GD: Pregnancy outcome in 21 patients with mild chronic hypertension. Obstet Gynecol, 61: 571–576, 1983.PubMedGoogle Scholar
  16. 16.
    Pritchard JA, MacDonald PC, Gant NF: Williiams Obstetrics, 17th edition, Appleton Century Crofts, Norwalk CT, 1985.Google Scholar
  17. 17.
    Wallenburg HCS: Hemodynamics in hypertensive pregnancy. In: “Hypertension in pregnancy” (Ed PC Rubin), Elsevier, New York, 1988, pp 66–101.Google Scholar
  18. 18.
    Kuzniar J, Skret A, Piela A, Szmiegel Z, Zaczek T: Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension. Obstet Gynecol, 66: 453–458, 1985.PubMedGoogle Scholar
  19. 19.
    Belfort M, Uys P, Dommisse J, Davey DA: Hemodynamic changes in gestational proteinuric hypertension: the effects of rapid volume expansion and vasodilator therapy. Br J Obstet Gynecol, 96: 634–641, 1989.Google Scholar
  20. 20.
    Jouppila P, Kirkinen P, Koivula A, Ylikorkala O: Effects of dihydralazine infusion on the fetoplacental blood flow and maternal prostanoids. Obstet Gynecol, 65: 115–118, 1985.PubMedGoogle Scholar
  21. 21.
    Nylund L, Lunell NO: Dihydralazine and the uteroplacental blood flow. Am J Obstet Gynecol, 158: 440–441, 1988 (Letter).PubMedGoogle Scholar
  22. 22.
    Suonio S, Saarikoski S, Tahvanainen K, Paakkonen A, Olkkonen H: Acute effects of dihydralazine mesylate, furosemide, and metoprolol on maternal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol, 155: 122–125, 1895.Google Scholar
  23. 23.
    Lipshitz J, Ahokas AR, Reynolds SL: The effect of hydralzine on placental perfusion in the spontaneously hypertensive rat. Am J Obstet Gynecol, 156: 356–359, 1987.PubMedGoogle Scholar
  24. 24.
    Vink GJ, Moodley J, Philpott RH: Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol, 55: 519–522, 1980.PubMedGoogle Scholar
  25. 25.
    Mabie WC, Gonzalez AR, Sibai BM, Amon E: A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol, 70: 328–333, 1987.PubMedGoogle Scholar
  26. 26.
    Harake B, Gilbert RD, Ashwal S, Power GG: Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Am J Obstet Gynecol, 157: 1003–1008, 1987.PubMedGoogle Scholar
  27. 27.
    Dusay CA, Cook MJ, Veille JC: Cardiorespiratory effects of calcium channel blocker tocolysis in pregnant rhesus monkeys. In: “The physiological development of the fetus and newborn” (Eds CT Jones, PW Nathanielsz), Academic Press, London, 1985, pp 423–428.Google Scholar
  28. 28.
    Parisi VM, Salinas J, Stockmar EJ: Fetal vascular responses to maternal nicardipine administration in the hypertensive ewe. Am J Obstet Gynecol, 161: 1035–1039, 1989.PubMedGoogle Scholar
  29. 29.
    Parisi VM, Salinas J, Stockmar EJ: Placental vascular responses to nicardipine in the hypertensive ewe. Am J Obstet Gynecol, 161: 1039–1043, 1989.PubMedGoogle Scholar
  30. 30.
    Ahokas RA, Sibai BM, Anderson GD: Nifedipine does not adversely affect uteroplacental blood flow in the hypertensive term-pregnant rat. Am J Obstet Gynecol, 159: 1440–1445, 1988.PubMedGoogle Scholar
  31. 31.
    Pirhonen JP, Erkkola RU, Ekblad U: Uterine and fetal flow velocity waveforms in hypertensive pregnancy: the effect of a single dose of nifedipine. Obstet Gynecol, 76: 37–41, 1990.PubMedGoogle Scholar
  32. 32.
    Hanretty KP, Whittle MJ, Howie CA, Rubin PC: Effect of nifedipine on doppler flow velocity waveforms in severe pre-eclampsia. Br Med J, 299: 1205–1206, 1989.Google Scholar
  33. 33.
    Mari G, Kirshon B, Moise KJ, Lee W, Cotton DB: Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am J Obstet Gynecol, 161: 1514–1518, 1989.PubMedGoogle Scholar
  34. 34.
    Lindow SW, Davies N, Davey DA, Smith JA: The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br J Obstet Gynecol, 95: 1276–1281, 1988.Google Scholar
  35. 35.
    Walters BNJ, Redman CWG: Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Br J Obstet Gynecol, 91: 330–336, 1984.Google Scholar
  36. 36.
    Fenakel K, Fenakel G, Appelman Z, Lurie S, Katz Z, Shoham Z: Nifedipine in the treatment of severe pre-eclampsia. Obstet Gynecol, 77: 331–337, 1991.PubMedGoogle Scholar
  37. 37.
    Walker JJ, Greer I, Calder AA: Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. Postgrad Med J, 52: 390–394, 1983.Google Scholar
  38. 38.
    Davey DA, Dommisse J, Garden A: Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. In: “The investigation of labetalol in the management of hypertension in pregnancy” (Eds A Riley, EM Symonds), Excerpta Medica, Amsterdam, 1982, pp 51–61.Google Scholar
  39. 39.
    Ashe RG, Moodley J, Richards AM, Philpott RH: Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afir Med J, 71: 354–356, 1987.Google Scholar
  40. 40.
    Lunell NO, Nylund L, Lewander R, Sarby B: Acute effect of an antihypertensive drug, labetalol, on uteroplacental blood flow. Br J Obstet Gynecol, 89: 640–644, 1982.Google Scholar
  41. 41.
    Sibai BM, Spinnato JA, Watson DL, Lewis JA, Anderson GD: Effect of magnesium sulphate on electroencephalographic findings in preeclampsia-eclampsia. Obstet Gynecol, 64: 261–266, 1984.PubMedGoogle Scholar
  42. 42.
    Thurnau GR, Kemp DB, Jarvis A: Cerebrospinal fluid levels of magnesium in patients with preeclampsia after treatment with intravenous magnesium sulphate: a preliminary report. Am J Obstet Gynecol, 157: 1435–1438, 1987.PubMedGoogle Scholar
  43. 43.
    Rothman SM, Olney JW: Excitotoxicity and the NMDA receptor. Trends Neurol Sci, 10: 299–302, 1987.Google Scholar
  44. 44.
    Rothman SM: Synaptic activity mediates death of hypoxic neurones. Science, 220: 536–537, 1984.Google Scholar
  45. 45.
    Finkbeiner S, Stevens CF: Application of quantitative measurements for assessing neurotoxicity. Proc Natl Acad Sci USA, 85: 4071–4074, 1988.PubMedGoogle Scholar
  46. 46.
    Pritchard JA, Cunningham FG, Pritchard SA: The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. Am J Obstet Gynecol, 148: 951–963, 1984.PubMedGoogle Scholar
  47. 47.
    Sibai BM: Magnesium sulphate is the ideal anticonvulsant in preeclampsia-eclampsia. Am J Obstet Gynecol, 162: 1141–1145, 1990.PubMedGoogle Scholar
  48. 48.
    Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr: Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia. Obstet Gynecol, 51: 199–202, 1981.Google Scholar
  49. 49.
    Lamm CI, Norton KI, Murphy RJC, Wilkins IA, Rabinowitz JG: Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr, 113: 1078–1082, 1988.PubMedGoogle Scholar
  50. 50.
    Crowther C: Magnesium sulphate versus diazepam in the management of eclampsia: a randomised controlled trial. Br J Obstet Gynecol, 97: 110–117, 1990.Google Scholar
  51. 51.
    Slater RM, Wilcox FL, Smith WD, Donnai P, Patrick J, Richardson T, Mawer GE, D’Souza SW, Anderton JM: Phenytoin infusion in severe pre-eclampsia. Lancet, I: 1417–1420, 1987.Google Scholar
  52. 52.
    Moosa SM, El Zayat SG: Phenytoin infusion in severe pre-eclampsia. Lancet, II: 1147–1148, 1987.Google Scholar
  53. 53.
    Tuffnell D, O’Donovan P, Lilford RJ, Prys-Davies A, Thornton JG: Phenytoin in pre-eclampsia. Lancet, I: 273–274, 1989.Google Scholar
  54. 54.
    Dommisse J: Phenytoin sodium and magnesium sulphate in the management of eclampsia. Br J Obstet Gynecol, 97: 104–109, 1990.Google Scholar
  55. 55.
    Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD: A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol, 162: 960–967, 1990.PubMedGoogle Scholar
  56. 56.
    Fidler J, Smith V, Fayers P, De Swiet M: Randomised controlled comparative study of methyldopa and Oxprenolol in treatment of hypertension in pregnancy. Br Med J, 286: 1927–1930, 1983.Google Scholar
  57. 57.
    Moar VA, Jefferies MA, Mutch LMM: Neonatal head circumference and the treatment of maternal hypertension. Br J Obstet Gynecol, 85: 933–937, 1978.Google Scholar
  58. 58.
    Ounsted MK, Moar VA, Good FJ, Redman CWG: Hypertension during pregnancy with and without specific treatment; the development of the children at the age of four years. Br J Obstet Gynecol, 87: 19–24, 1980.Google Scholar
  59. 59.
    Cockburn J, Moar VA, Ounsted M, Redman CWG: Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet, I: 647–649, 1982.Google Scholar
  60. 60.
    Hogstedt S, Lindeberg S, Axelsson O et al: A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy. Acta Obstet Gynecol Scand, 64: 505–510, 1985.PubMedGoogle Scholar
  61. 61.
    Bott-Kanner G, Schweitzr A, Reisner SH, Joel-Cohen SJ, Rosenfeld JB. Propranolol and hydralazine in the management of essential hypertension in pregnancy. Br J Obstet Gynecol, 87: 110–114, 1980.Google Scholar
  62. 62.
    Rosenfeld J, Bott-Kanner G, Boner G et al: Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Eur J Obstet Gynecol Reprod Biol, 22:197–204, 1986.PubMedGoogle Scholar
  63. 63.
    Widerlov E, Karlman I, Storsater J: Hydralazine-induced neonatal thrombocytopenia N Engl J Med, 303: 1235–1237, 1980.PubMedGoogle Scholar
  64. 64.
    Lieberman BA, Stirrat GM, Donen SL, Beard RW, Pinker GD, Belsey E: The possible adverse effect of propranolol on the fetus in pregnancies complicated by severe hypertension. Br J Obstet Gynecol, 85: 678–683, 1978.Google Scholar
  65. 65.
    Jouppila P, Kirkinen P, Koivula A, Ylikorkala O: Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia. Br J Obstet Gynecol, 93: 543–547, 1986.Google Scholar
  66. 66.
    Haraldsson A, Geven W: Serious adverse effects of maternal labetalol in a premature infant. Acta Pediatr Scand, 78: 956–958, 1989.Google Scholar
  67. 67.
    Woods DL, Morrell DF: Atenolol: side effects in a newborn infant. Br Med J, 285: 691–692, 1982.Google Scholar
  68. 68.
    Macpherson M, Broughton Pipkin F, Rutter N: The effect of maternal labetalol on the newborn infant. Br J Obstet Gynecol, 93: 539–542, 1986.Google Scholar
  69. 69.
    Dumez Y, Tchobroutsky, Hornych H, Amiel-Tsion C: Neonatal effects of maternal administration of acebutolol. Br Med J, 283: 1077–1079, 1981.Google Scholar
  70. 70.
    Sibai BM, Gonzalez AR, Mabie WC, Moretti M: A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol, 70: 323–327, 1987.PubMedGoogle Scholar
  71. 71.
    Pickles CJ, Symonds EM, Broughton Pipkin F: The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynecol, 96: 38–43, 1989.Google Scholar
  72. 72.
    Plouin PF, Breart G, Llado J, Dalle M, Keller ME, Goujon H, Berchel C: A randomised comparison or early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynecol, 97: 134–141, 1990.Google Scholar
  73. 73.
    Reynolds B, Butters L, Evans J, Adams T, Rubin PC: First year of life after the use of atenolol in pregnancy associated hypertension. Arch Dis Child, 59: 1061–1063, 1984.PubMedGoogle Scholar
  74. 74.
    Constantine G, Beevers DG, Reynolds AL, Luesley DM: Nifedipine as a second line antihypertensive drug in pregnancy. Br J Obstet Gynecol, 94: 1136–1142, 1987.Google Scholar
  75. 75.
    Schubiger G, Flury G, Nussberger J: Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med, 108: 215–216, 1988.PubMedGoogle Scholar
  76. 76.
    Broughton Pipkin F, Symonds EM, Turner SR: The effect of Captopril (SQ14225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. J Physiol, 323: 415–422, 1982.Google Scholar
  77. 77.
    Ferris TF, Weir EK: Effect of Captopril on uterine blood flow and prostaglandin synthesis in the pregnant rabbit. J Clin Invest, 71: 809–815, 1983.PubMedGoogle Scholar
  78. 78.
    Lubbe WF, Hodge JV: Combined alpha and beta-adrenceptor antagonism with prazosin and Oxprenolol in control of severe hypertension in pregnancy. NZ Med J, 94: 169–172, 1981.Google Scholar
  79. 79.
    Dommisse J, Davey DA, Roos PJ: Prazosin and Oxprenolol therapy in pregnancy hypertension. S Afr Med J, 64: 231–233, 1983.PubMedGoogle Scholar
  80. 80.
    Rubin PC, Butters L, Low RA, Reid JL. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. Br J Clin Pharmacol, 16: 543–547, 1983.PubMedGoogle Scholar
  81. 81.
    Devoe LD, O’Dell BE, Castillo RA, Hadi HA, Saerle N: Metastatic phaeochromocytoma in pregnancy and fetal biophysical assessment after maternal administration of alpha-adrenergic, beta-adrenergic and dopamine antagonists. Obstet Gynecol, 68 (Suppl): 15S–18S, 1986.PubMedGoogle Scholar
  82. 82.
    Venuto R, Burstein P, Schneider R: Phaeochromocytoma: antepartum diagnosis and management with tumor resection in the Puerperium. Am J Obstet Gynecol, 150: 431–432, 1984.PubMedGoogle Scholar
  83. 83.
    Belizan JM, Villar J, Repke J: The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence. Am J Obstet Gynecol, 158: 898–902, 1988.PubMedGoogle Scholar
  84. 84.
    Taufield PA, Ales KL, Resnick LM, Druzin ML, Gertner JM, Laragh JH: Hypocalciuria in preeclampsia. N Engl J Med, 316: 715–718, 1987.PubMedGoogle Scholar
  85. 85.
    Kawasaki N, Matsui K Ito M et al: Effect of calcium supplementation on the vascular sensitivity to angiotensin II in pregnant women. Am J Obstet Gynecol, 153: 576–582, 1985.PubMedGoogle Scholar
  86. 86.
    Montanaro D, Bascutti G, Antonucci F, et al: Prevention of pregnancy-induced hypertension (PIH) and preeclampsia (PE) by oral calcium supplementation. 10th Int Congress Nephrol: 291, 1987, (Abstract).Google Scholar
  87. 87.
    Bamford DS, Jogee M, Williams KI: Prostacyclin formation by pregnant human myometrium. Br J Obstet Gynecol, 87: 215, 1980.Google Scholar
  88. 88.
    Mitchell MD, Bibby JB, Hicks BR, Tumbull AC: Possible role for prostacyclin in human parturition. Prostaglandins, 16: 931, 1978.PubMedGoogle Scholar
  89. 89.
    Rakoczi I, Tihanyi K, Falkay G, Rosza I, Demaler J, Gati I: Prostacyclin production in trophoblast. In: “Prostacyclin and pregnancy” (Eds PJ Lewis, S Moncada, J O’Grady), Raven Press, New York, 1983, pp 15–23.Google Scholar
  90. 90.
    Spitz B, Deckmyn H, van Assche FA, Vermylen J: Prostacyclin production in whole blood throughout normal pregnancy. In: “Clinical and experimental hypertension. Part B. Hypertension in pregnancy” (Eds FP Zuspan, EM Symonds), Marcel Dekker, New York, 1983, pp 191–202.Google Scholar
  91. 91.
    Mitchell MD: Prostacyclin during human pregnancy and parturition. In: “Clinical pharmacology of prostacyclin” (Eds PJ Lewis, J O’Grady), Raven Press, New York, 1981, pp 121–129.Google Scholar
  92. 92.
    Ylikorkola O, Viinikka L: Maternal plasma levels of 6-keto-prostaglandin F1-alpha during pregnancy and Puerperium. Prostaglandins Leukotrienes Med, 7: 95, 1981.Google Scholar
  93. 93.
    Koullapis EN, Nicolaides KH, Collins WP, Rodeck CH, Campbell S: Plasma prostanoids in pregnacy-induced hypertension. Br J Obstet Gynecol, 89: 617, 1982.Google Scholar
  94. 94.
    Lewis PJ, Boylan P, Friedman LA, Hensby CN, Downing I: Prostacyclin in pregnancy. Br Med J, 280: 1581, 1980.PubMedGoogle Scholar
  95. 95.
    Fitzgerald DJ, Entman SS, Mulloy K, Fitzgerald GA: Decreased prostacyclin biosynthesis preceeding the clinical manifestation of pregnancy-induced hypertension. Circ, 5: 956–963, 1987.Google Scholar
  96. 96.
    Fitzgerald DJ, Mayo G, Catella F, Entman SS, Fitzgerald GA: Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets. Am J Obstet Gynecol, 157: 325–330, 1987.PubMedGoogle Scholar
  97. 97.
    Fitzgerald DJ, Rocki W, Murray R, Mayo G, Fitzgerald GA: Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet, 335: 751–754, 1990.PubMedGoogle Scholar
  98. 98.
    Sibai BM, Mirro R, Chesney CM, Leffler C: Low-dose aspirin in pregnancy. Obstet Gynecol, 74: 551–556, 1989.PubMedGoogle Scholar
  99. 99.
    Nelson DM, Walsh SW: Aspirin differentially affects thromboxane and prostacyclin production by trophoblast and villous core compartments of human placental villi. Am J Obstet Gynecol, 161: 1593–1598, 1989.PubMedGoogle Scholar
  100. 100.
    Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, Barkai G, Ben-Baruch G, Yahal I, Blankstein J, Goldman B, Mashiach S: The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med, 321: 351–356, 1989.PubMedGoogle Scholar
  101. 101.
    Benigni A, Gregorina G, Frasca T, Chiabrando C, Ballerini S, Valcamonico A, Orisio s, Piccinelli A, Pinciroli V, Fanelli R, Gastaldi A, Remuzzi G: Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med, 321: 357–362, 1989.PubMedGoogle Scholar
  102. 102.
    Stuart MJ, Gross SJ, Elrad H, Graeber JE: Effects of acetylsalicylic-acid on maternal and neonatal hemostasis. N Engl J Med, 307: 909–912, 1982.PubMedGoogle Scholar
  103. 103.
    Beaufils M, Uzan S, Donsimoni R, Colau JC: Prevention of pre-eclampsia by early antiplatelet therapy. Lancet, I: 840–842, 1985.Google Scholar
  104. 104.
    Wallenburg HCS, Dekker GA, Makovitz JW, Rotmans P: Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive Primigravidae. Lancet, I: 1–3, 1986.Google Scholar
  105. 105.
    McParland P, Pearce JM, Chamberlain GVP: Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet, 335: 1552–1555, 1990.PubMedGoogle Scholar
  106. 106.
    Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J: Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet, 337: 1427–1431, 1991.PubMedGoogle Scholar
  107. 107.
    Zierler S, Rothman KJ: Congenital heart disese in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med, 313: 347–352, 1985.PubMedGoogle Scholar
  108. 108.
    Werler MM, Mitchell AA, Shapiro S: The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med, 321: 1639–1642, 1989.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1991

Authors and Affiliations

  • Stephen N. Sturgiss
    • 1
  • Marshall D. Lindheimer
    • 2
  • John M. Davison
    • 1
  1. 1.Department of Obstetrics and GynaecologyUniversity of Newcastle-upon-Tyne, Princess Mary Maternity HospitalNewcastle-upon-TyneUK
  2. 2.Departments of Medicine and Obstetrics and GynecologyUniversity of Chicago, Chicago Lying-in HospitalChicagoUSA

Personalised recommendations